GlassScriptPhysician profile
Nicole D Englert
NPI 1104993674
$12,269.40
in general payments reported to CMS, 2019-2025
38 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,998 · 2022: $2,262 · 2023: $2,305 · 2024: $3,341 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,857 · Consulting Fee: $122 · Education: $30.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,856.98 |
| Consulting Fee | $121.66 |
| Education | $30.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,199.43 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,108.96 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,044.35 | 2021-2025 | Cuvitru, Hyqvia, Eohilia |
| Regeneron Healthcare Solutions, INC. | $865.53 | 2021-2025 | Dupixent |
| Genzyme Corporation | $722.36 | 2021-2025 | |
| Leo Pharma INC. | $679.78 | 2022-2025 | Adbry, Anzupgo |
| Optinose US, INC. | $534.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $489.32 | 2021-2025 | |
| Genentech USA, INC. | $427.54 | 2021-2025 | Xolair |
| Grifols USA, LLC | $357.62 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Abbvie INC. | $323.98 | 2022-2025 | |
| Pfizer INC. | $318.63 | 2021-2023 | |
| Amgen INC. | $276.03 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $216.89 | 2021-2024 | Yupelri |
| Biocryst US Sales Co., LLC | $205.98 | 2021-2025 | Orladeyo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $173.42 | 2021-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.63 | 2021-2022 | |
| Adma Biomanufacturing LLC | $148.81 | 2022-2025 | |
| Csl Behring | $143.07 | 2022-2025 | Hizentra, Haegarda |
| Pharming Healthcare, INC. | $134.09 | 2021-2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $133.97 | 2021-2022 | |
| Incyte Corporation | $96.89 | 2023-2025 | Opzelura |
| Baxter Healthcare | $90.82 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Kedrion Biopharma, INC. | $68.35 | 2024 | Koate, Kedrab, Albuked |
| Lilly USA, LLC | $59.58 | 2025 | Ebglyss |
| Bio Products Laboratory USA, INC. | $52.39 | 2022-2023 | Coagadex, Gammaplex |
| Blueprint Medicines Corporation | $31.65 | 2022-2023 | Ayvakit |
| Actelion Pharmaceuticals US, INC. | $24.68 | 2022 | |
| Sunovion Pharmaceuticals INC. | $24.66 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $21.20 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $20.06 | 2025 | Dawnzera |
| Electromed, INC. | $18.55 | 2021 | |
| Phadia US INC. | $18.52 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $18.31 | 2023 | |
| Viatris Specialty LLC | $17.90 | 2025 | Yupelri |
| Eyevance Pharmaceuticals LLC | $15.57 | 2021 | |
| Advanced Respiratory, INC | $14.60 | 2021 | |
| Cycle Pharmaceuticals INC | $12.20 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Englert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.